(0.28%) 5 105.75 points
(0.66%) 38 635 points
(0.56%) 17 749 points
(0.30%) $79.19
(0.10%) $2.04
(0.03%) $2 310.20
(0.02%) $26.84
(1.15%) $973.70
(-0.14%) $0.931
(-0.50%) $10.94
(-0.19%) $0.796
(0.70%) $91.76
Live Chart Being Loaded With Signals
C4X Discovery Holdings plc operates as a drug discovery company in the United Kingdom. The company provides Taxonomy3, a novel in silico platform technology that utilizes proprietary mathematical algorithms to perform complex multivariate analysis of genetic data; Conformetrix, a technology platform which allows 3D-shapes of free drug molecules to be measured from experimental data, giving medicinal chemists new and unprecedented insights into the behavior and physical properties of drug molecules; and 4Sight for visualizing 4D molecules in virtual reality...
Stats | |
---|---|
本日の出来高 | 27.55M |
平均出来高 | 1.13M |
時価総額 | 30.27M |
EPS | £0 ( 2024-04-23 ) |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | 3.00 |
ATR14 | £1.896 (15.80%) |
ボリューム 相関
C4X Discovery Holdings 相関
10 最も正の相関 | |
---|---|
NVT.L | 0.95 |
MCL.L | 0.942 |
MAST.L | 0.942 |
ORCA.L | 0.939 |
ETX.L | 0.938 |
GRL.L | 0.936 |
MOTR.L | 0.933 |
CCZ.L | 0.931 |
AVO.L | 0.928 |
MIRI.L | 0.928 |
10 最も負の相関 | |
---|---|
BILN.L | -0.946 |
JPSA.L | -0.924 |
JGSA.L | -0.917 |
MPO.L | -0.915 |
FEDF.L | -0.913 |
TFRN.L | -0.912 |
XFFE.L | -0.912 |
DEMR.L | -0.904 |
K3C.L | -0.901 |
MAFL.L | -0.894 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
C4X Discovery Holdings 相関 - 通貨/商品
C4X Discovery Holdings 財務諸表
Annual | 2023 |
収益: | £1.71M |
総利益: | £1.67M (97.78 %) |
EPS: | £-0.0442 |
FY | 2023 |
収益: | £1.71M |
総利益: | £1.67M (97.78 %) |
EPS: | £-0.0442 |
FY | 2022 |
収益: | £2.70M |
総利益: | £2.57M (95.18 %) |
EPS: | £-0.0357 |
FY | 2021 |
収益: | £5.64M |
総利益: | £5.55M (98.40 %) |
EPS: | £-0.0400 |
Financial Reports:
No articles found.
C4X Discovery Holdings
C4X Discovery Holdings plc operates as a drug discovery company in the United Kingdom. The company provides Taxonomy3, a novel in silico platform technology that utilizes proprietary mathematical algorithms to perform complex multivariate analysis of genetic data; Conformetrix, a technology platform which allows 3D-shapes of free drug molecules to be measured from experimental data, giving medicinal chemists new and unprecedented insights into the behavior and physical properties of drug molecules; and 4Sight for visualizing 4D molecules in virtual reality. The company's product pipeline includes Orexin-1, a receptor antagonist for the treatment of addictive disorders; NRF-2 activator to treat various inflammatory diseases; IL-17A inhibitor for inflammation and autoimmune diseases; a4ß7 integrin inhibitors for the treatment of inflammatory bowel disease; and MALT-1 inhibitors to treat hematological cancer. It has partnerships with Sanofi, GEN-COVID, LifeArc, Indivior PLC, Phoremost, AstraZeneca UK Limited, and Evotec SE. The company was formerly known as Schosween 24 plc and changed its name to C4X Discovery Holdings plc October 2014. C4X Discovery Holdings plc was incorporated in 2007 and is based in Manchester, the United Kingdom.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。